Ann: Appendix 4C - Quarterly Cash Flow-OSL.AX, page-13

osl's brachy option has passed in vivo testing and will inevitably achieve superior dose delivery with lower gut toxicity cf external beam radiotherapy/ cyberknife.
the main issue is not respiratory movement but gut toxicity at high effective doses which is unavoidable with any external technique even with imrt/ conformal 3D ebrt.
i prefer oncosil to the competitor but both have potential.
endoscopic ultrasound (eus) is the delivery method via stomach/ dudmodenun as it commonly done already for biopsies etc.
psma is takeb up by pancreas and salivary glands but less avidly than prostate so i havnt seen any good data for its efficacy in pancreatic ca (although i agree it is worth exploring).
i dont see any problem accessing tail of pancreas lesions or large nodes in the portahepatis/ coeliac/ sma regions (if a single large node at risk of local compression of surrounding structures).

i cant predict ce mark for sure and understand the wise scepticism of long term holders who are growing impatient, but i would have thought you would kick yourself if you sold and it popped up on approval a month or two later.

management will not have forgotten that they have not met their previous timeline predictions and they will be feeling pressure to deliver as a matter of urgency to protect their own equity and solidify the confidence of investors